Tempus AI Inc. agreed to buy cancer-testing company Personalis Inc. for $1.7 billion, according to Bloomberg.
The deal adds Personalis, which focuses on cancer testing, to Tempus AI's healthcare technology platform.
Tempus AI to Buy Personalis for $1.7 Billion
2026-07-20 13:02:59
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
